Chen 2015.
| Methods | 60 AGC participants randomly divided into 2 groups by "random number table" ‐ 30 vs 30 | |
| Participants | Age range 18‐75 years Males:Females ratio was 18:12 in the DSOX group and 14:16 in the DCF group |
|
| Interventions | Docetaxel plus S1 plus oxaliplatin (DSOX) vs Docetaxel plus fluorouracil plus cisplatin (DCF) | |
| Outcomes | OS TTP Tumour response |
|
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | "Random number table" |
| Allocation concealment (selection bias) | Unclear risk | Not stated |
| Incomplete outcome data (attrition bias) efficacy | Unclear risk | 2 patients lost to follow‐up, reasons not stated |
| Incomplete outcome data (attrition bias) safety | Unclear risk | 2 patients lost to follow‐up, reasons not stated |
| Selective reporting (reporting bias) | Unclear risk | Not clear how many were screened for eligibility and randomised. Only the number of evaluable patients are provided. |
| Other bias | Unclear risk | Nothing to comment on |
| Blinded review of CT/MRI‐scans? | Unclear risk | Not stated |